Invitae Non-invasive Prenatal Screening

Give your pregnant patients the genetic insights they want, and more.


Invitae Non-invasive Prenatal Screening (NIPS)

  • Our high-quality, affordable NIPS can detect fetal chromosomal abnormalities as early as 10 weeks, for all pregnant patients.

  • Invitae NIPS quickly analyzes cell-free DNA (cfDNA) to assess whether a singleton or twin pregnancy is at increased risk for the three most common chromosomal disorders on chromosomes 21, 18, and 13.

  • Add optional microdeletion and sex chromosome analysis at no additional charge, or pair with carrier screening for even more insights.

The American College of Obstetricians and Gynecologists recommends offering aneuploidy screening to all women, regardless of maternal age. NIPS is the most accurate aneuploidy screen.1,2

Invitae NIPS detects:

  • Trisomy 21 (Down syndrome)

  • Trisomy 18 (Edwards syndrome)

  • Trisomy 13 (Patau syndrome)

Go even deeper with Invitae’s optional add-ons offered at no additional charge

Assess clinically significant microdeletions, determine the risk of sex chromosome disorders, and predict fetal sex—all in one test, at one affordable price.

Microdeletion add-on

Detect five clinically significant microdeletion regions to screen for syndromes that may be undetectable by ultrasound and other early screening technologies.
Microdeletions detected:
  • 1p36 deletion syndrome
  • DiGeorge syndrome (22q11.2 deletion syndrome)
  • Angelman/Prader-Willi syndrome (15q11.2 deletion syndrome)
  • Cri du Chat syndrome (5p15.2 deletion)
  • Wolf-Hirschhorn syndrome (4p16.3 deletion)

Sex chromosome add-on

Predict fetal sex as early as 10 weeks and simultaneously detect aneuploidies to determine the risk of sex chromosome disorders.
Aneuploidies detected:
  • Turner syndrome (monosomy X)
  • Triple X syndrome (47,XXX)
  • Klinefelter syndrome (47,XXY)
  • Jacob’s syndrome (47,XYY)

Invitae NIPS for twins

  • Assess whether a twin pregnancy is at increased risk for the three most common chromosomal disorders on chromosomes 21, 18, and 13.
  • Invitae’s optional sex chromosome add-on for twins can determine the presence of a Y chromosome at no additional charge.
  • Sex chromosome aneuploidy and microdeletion for twin pregnancies are not available.


Lowest published failure rate in the industry

Our technology, which uses whole-genome sequencing, offers the lowest published failure rate in the industry, 0.1%.3-7

Positive predictive value (PPV)

  • Every positive report contains a PPV for chromosomes 21, 18, and 13
  • PPV is calculated for each patient using individual maternal age and gestational age

Fetal fraction

  • Each result report includes fetal fraction, the percentage of fetal DNA (placental cell-free DNA) present in the sample. Invitae’s technology is optimized to handle samples at the low end of the fetal fraction rate to deliver more accurate results.

Invitae NIPS + Invitae Carrier Screen

Expand your patient’s early prenatal care. Easily add Invitae carrier screening to your Invitae NIPS order to discover even more insights from one streamlined specimen collection kit.

Simplified workflow

Receive an email when your patient’s results are ready (5-7 days on average) and be notified via text message for urgent review of positive results.

Easily access results and resources in Invitae’s HIPAA-compliant online portal. Invitae’s straightforward reports come with next step recommendations for your patient’s prenatal care.

Auto-release your patient's negative results so they can easily take advantage of Invitae's interactive patient portal.

Access your patient's consultation notes from their genetic counseling session with Invitae.

Order follow-up prenatal diagnostic testing if necessary.

How it works

Request a free specimen collection kit online.

Order a test using Invitae’s HIPAA-compliant online portal or on a paper TRF.

Receive an email or text message when your results are ready (5-7 days on average). Have questions about results or their clinical implications? Our team of board-certified genetic counselors is available to discuss.

Get actionable insights to inform your patient’s care.

More insights with Invitae's broad test menu

From screening to diagnosis, Invitae has the right test for each patient, no matter where they are in their pregnancy journey.

Pair carrier screening

with NIPS for comprehensive early pregnancy genetic analysis.

Learn more

Confirm positive NIPS

with Invitae’s prenatal diagnostic tests.

Learn more

Uncover the cause

of recurrent miscarriage with Invitae’s chromosomal microarray analysis.

Learn more

The Invitae advantage

Affordable pricing

Invitae is committed to offering flexible options and affordable pricing as part of our mission to make genetic testing accessible to all.

NIPS patient-pay price is just $99.  

Learn more

Flexible billing options

Invitae is proud to be in-network for more than 270 million patients.

For patients without coverage, we also offer a financial assistance program.

Learn more

Hands-on clinical support

Invitae’s team of genetic experts provide peer support for clinicians and post-test counseling for patients at no additional charge.

Learn more

Take the first step by requesting a free specimen collection kit today.

Request a kit


  1. Practice Bulletin No. 163: Screening for fetal aneuploidy. Obstet Gynecol. 2016;127(5):979-81.
  2. Gregg AR, Skotko BG, Benkendorf JL et al. Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics. Genet Med. 2016;18(10):1056-65.
  3. Taneja PA, Snyder HL, de Feo E et al. Noninvasive prenatal testing in the general obstetric population: clinical performance and counseling considerations in over 85 000 cases. Prenat Diagn. 2016;36(3):237-243.
  4. McCullough RM, Almasri EA, Guan X et al. Non-invasive prenatal chromosomal aneuploidy testing--clinical experience: 100,000 clinical samples. PLoS One. 2014;9(10):e109173.
  5. Ryan A, Hunkapiller N, Banjevic M et al. Validation of an enhanced version of a single-nucleotide polymorphism-based noninvasive prenatal test for detection of fetal aneuploidies. Fetal Diagn Ther. 2016;40(3):219-23.
  6. Yaron Y. The implications of non-invasive prenatal testing failures: a review of an under-discussed phenomenon. Prenat Diagn. 2016;36(5):391-6.
  7. Norton ME, Jacobsson B, Swamy GK et al. Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med. 2015;372:1589-97.